Pieris Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Palvella Therapeutics announced positive Phase 3 clinical trial results for QTORIN rapamycin in microcystic lymphatic malformations and secured $215.8 million in a public offering, despite ongoing operating losses.
Palvella Therapeutics (PVLA) shifts focus to rare genetic skin diseases following a reverse merger, advancing QTORIN rapamycin clinical trials.
10-K/A: Pieris Pharmaceuticals Files Amended 10-K Report, Details Executive Compensation and Governance
Pieris Pharmaceuticals has filed an amendment to its annual report on Form 10-K, primarily to include previously omitted information regarding executive compensation, corporate governance, and related matters.
10-K: Pieris Pharmaceuticals Implements Strategic Shift, Focuses on Partnered Assets and Cost Reduction
Pieris Pharmaceuticals will discontinue research and development, reduce its workforce, and focus on partnered immuno-oncology assets to extend its cash runway into 2027.